Published in Anal Biochem on May 15, 1992
Attacking cancer at its foundation. Nat Med (2009) 0.83
2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase. Br J Pharmacol (2010) 0.79
Development of a sensitive non-radioactive protein kinase assay and its application for detecting DYRK activity in Xenopus laevis oocytes. BMC Biochem (2010) 0.78
An ELISA DYRK1A non-radioactive kinase assay suitable for the characterization of inhibitors. F1000Res (2017) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med (1977) 8.24
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 5.09
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes Dev (1998) 2.30
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
Retracted Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A (1995) 1.93
Evidence that the reactivity of the martian soil is due to superoxide ions. Science (2000) 1.87
Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem (1995) 1.81
Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem (1995) 1.69
Studies of the continuing susceptibility of group A streptococcal strains to penicillin during eight decades. Pediatr Infect Dis J (1998) 1.54
Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry (2011) 1.52
Autoimmune encephalopathy presenting as a 'posterior circulation stroke'. J Neurol (2010) 1.45
First MR images obtained during megavoltage photon irradiation from a prototype integrated linac-MR system. Med Phys (2009) 1.43
Two different species of murein transglycosylase in Escherichia coli. J Bacteriol (1980) 1.42
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis (1997) 1.34
Soluble nascent peptidoglycan in growing Escherichia coli cells. J Biol Chem (1980) 1.26
Effects of low concentrations of antibiotics on Escherichia coli adhesion. Antimicrob Agents Chemother (1982) 1.25
Patient dosimetry for hybrid MRI-radiotherapy systems. Med Phys (2008) 1.22
The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem (1999) 1.22
S-cyclophilin. New member of the cyclophilin family associated with the secretory pathway. J Biol Chem (1991) 1.20
Temperature rises produced by light sources and composites during curing. Dent Mater (1986) 1.20
Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob Agents Chemother (1997) 1.17
Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood (1994) 1.16
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem (1997) 1.13
Cardiac risk factors and complications in non-cardiac surgery. Medicine (Baltimore) (1978) 1.10
Services to families of adults with schizophrenia: from treatment recommendations to dissemination. Psychiatr Serv (1999) 1.09
Loss of insight in frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy. Brain (2007) 1.08
CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res (1994) 1.07
Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus. J Cell Biochem (1992) 1.06
Lung dosimetry in a linac-MRI radiotherapy unit with a longitudinal magnetic field. Med Phys (2010) 1.05
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. J Biol Chem (1990) 1.05
Evaluation of renal transplant rejection by duplex Doppler examination: value of the resistive index. AJR Am J Roentgenol (1987) 1.05
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res (1998) 1.02
Retracted 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci U S A (1994) 1.01
Properties of pili from Escherichia coli SS142 that mediate mannose-resistant adhesion to mammalian cells. J Bacteriol (1983) 0.98
In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrob Agents Chemother (1996) 0.98
Sleep states in the newborn: influence of sound. Neuropadiatrie (1971) 0.97
Stable amplification of the S-adenosylmethionine decarboxylase gene in Chinese hamster ovary cells. J Biol Chem (1995) 0.95
2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett (1999) 0.94
Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol (1999) 0.94
Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem (1994) 0.92
Physiological studies of the regulation of beta-lactamase expression in Pseudomonas maltophilia. J Bacteriol (1989) 0.92
New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity. Cancer Res (1992) 0.92
Penems: in vitro and in vivo experiments. J Clin Pharmacol (1988) 0.92
Palliative radiotherapy for women with breast cancer. Clin Oncol (R Coll Radiol) (2008) 0.90
Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm (Weinheim) (1996) 0.90
Urinary collagen IV and πGST: potential biomarkers for detecting localized kidney injury in diabetes--a pilot study. Am J Nephrol (2010) 0.90
Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J Biol Chem (1996) 0.89
Preliminary studies on the gastrointestinal responses to fatty meals in obese people. Int J Obes Relat Metab Disord (1993) 0.89
Adaptation to high-fat diets: effects on eating behaviour and plasma cholecystokinin. Br J Nutr (1995) 0.88
Duodeno-pancreatic secretions enhance bactericidal activity of antimicrobial drugs. Antimicrob Agents Chemother (1984) 0.88
Closure of fornix-based posttrabeculectomy conjunctival wound leaks with autologous fibrin glue. Am J Ophthalmol (1992) 0.88
Safety and efficacy of increasing wintertime vitamin D and calcium intake by milk fortification. QJM (1995) 0.88
Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med (2006) 0.88
S-adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone). J Med Chem (1993) 0.88
Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther (1999) 0.88
4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem (1996) 0.88
Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem (1999) 0.87
An exploration of evolved mental mechanisms for dominant and subordinate behaviour in relation to auditory hallucinations in schizophrenia and critical thoughts in depression. Psychol Med (2001) 0.87
Immunochemical mapping of alpha-2 interferon. Biochemistry (1985) 0.87
Localization of the heparin-binding site of glia-derived nexin/protease nexin-1 by site-directed mutagenesis. Biochemistry (1994) 0.86
2-substituted 3-(aminooxy)propanamines as inhibitors of ornithine decarboxylase: synthesis and biological activity. J Med Chem (1992) 0.86
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. J Pharm Belg (1997) 0.86
Radio frequency noise from clinical linear accelerators. Phys Med Biol (2009) 0.86
[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase. J Med Chem (1995) 0.85
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin Cancer Res (1995) 0.85
4-Amidinoindan-1-one 2'-amidinohydrazone: a new potent and selective inhibitor of S-Adenosylmethionine decarboxylase. J Med Chem (1993) 0.85
Improving the quality of healthcare for children: implementing the results of the AHSR research agenda conference. Health Serv Res (1998) 0.84
Fimbria-specific antibodies detach Escherichia coli from human cells. Infect Immun (1983) 0.84
CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme. Biochem J (1997) 0.84
Handedness in childhood autism shows a dissociation of skill and preference. Cortex (1992) 0.84
Active baculovirus recombinant p70s6k and p85s6k produced as a function of the infectious response. J Biol Chem (1993) 0.84
Linear accelerator photon beam quality at off-axis points. Med Phys (1997) 0.83
Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors. Eur J Biochem (1992) 0.83
Masseter and temporalis muscle EMG levels and bite force in migraineurs. Headache (2001) 0.83
Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. Aust N Z J Ophthalmol (1996) 0.82
Cdc2-mediated modulation of pp60c-src activity. J Biol Chem (1994) 0.82
An ELISA capture assay for the E7 transforming proteins of HPV16 and HPV18. J Virol Methods (1992) 0.82
Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase. Biochem J (1992) 0.82
Audit of an inpatient neurology consultation service in a tertiary referral centre: value of the consulting neurologist. Ir Med J (2005) 0.82
Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors. Structure (1997) 0.81
Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src. Oncogene (1999) 0.81
A double-blind randomized vehicle-controlled clinical trial investigating the effect of ZnPTO dose on the scalp vs. antidandruff efficacy and antimycotic activity. Int J Cosmet Sci (2003) 0.81
Deliberate self poisoning with antidepressant drugs: a comparison of the relative hospital costs of cases of overdose of tricyclics with those of selective-serotonin re-uptake inhibitors. J Affect Disord (2000) 0.81
Sebaceous lymphadenoma of the parotid gland. Dentomaxillofac Radiol (2008) 0.80
Pharmacodynamics of warfarin at steady state. Ther Drug Monit (1987) 0.80